Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI wearable could spot Parkinson's freezing episodes at home

NCT ID NCT07580612

Knowledge-focused Sponsor: KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an artificial intelligence algorithm that uses wearable sensors to detect freezing of gait—a sudden inability to walk—in people with Parkinson's disease. Researchers want to see if the AI works accurately in home environments, not just in the lab. About 126 participants will wear sensors and perform walking tasks while being video-recorded for comparison. The goal is to improve fall risk monitoring and eventually enable real-time detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
artificial intelligence algorithm for gait analysis
What this could lead to
If successful, this could lead to a reliable home-based tool to automatically detect freezing of gait, helping doctors assess fall risk without requiring clinic visits.
What could go wrong
This is an early-stage validation study in a home setting, so the algorithm may not perform as well outside the lab. It is not a treatment and does not directly improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with PD and healthy age-matched controls will be recruited from three primary sites, namely KU Leuven, Hamburg Medical Center, and Tel-Aviv Sourasky Medical Center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all participants * Voluntary written informed consent of the participant has been obtained prior to any study-related procedures, except the non-recorded pre-screening questions; * At least 18 years of age at the time of signing the Informed Consent Form (ICF); * Person is cognitively able to follow and understand instructions and provide voluntary written informed consent; * Person is able to walk for short distances (± 10 meters) independently, with- or without use of a walking aid; * Person does not live in a temporary or permanent care facility. For participants with PD: * Clinical diagnosis of Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines; * Person self-reports to experience daily FOG (for recruitment of freezers only); * Person is willing to temporarily delay the morning anti-Parkinsonian medication during the standardized assessment visit. Exclusion criteria: * Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait; * Participant self-reports daily falls; * Participation in another interventional study, with or without an investigational medicinal product (IMP) or device (IMD)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artifical intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artifical intelligence Freezing of gait Parkinson disease, idiopathic Validation Wearable sensors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for the study of movement, cognition and mobility

    NOT_YET_RECRUITING

    Tel Aviv, 64, Israel

  • Department of Rehabilitation Sciences

    RECRUITING

    Leuven, 3001, Belgium

  • Sports Science and Neurorehabilitation

    NOT_YET_RECRUITING

    Hamburg, 20457, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.